Diabetes prevalence, awareness, and control in the United States, 2017-2023
Authors' conclusion
Between 2017-2020 and 2021-2023, there were no significant changes in diabetes prevalence, awareness, and control in the U.S.
Study context
- Population
- Non-pregnant US adults aged ≥20 years who had undergone biomedical testing, NHANES
- Exposure
- Post-pandemic vs pre-pandemic
- Outcome
- Prevalence of total, diagnosed and undiagnosed diabetes (undiagnosed: no self-reported DM with HbA1c >6.5 % or FPG ≥126 mg/dL)
Methodological detailsrepeated national surveys (NHANES)
- Repeated national surveys (NHANES)
Main finding
As reported in the abstract
Prevalence of total diabetes
Observational data: associations, not effects.
Further findings
%
| Outcome | Pre-pandemic | Post-pandemic |
|---|---|---|
| Prevalence of diagnosed diabetes | 11.7 (CI 10.1–13.2) | 11.3 (CI 9.4–13.2) |
| Prevalence of undiagnosed diabetes | 4.6 (CI 3.8–5.3) | 4.5 (CI 3.4–5.6) |
| Proportion of diabetes that was undiagnosed | 28.1 (CI 24.3–31.8) | 28.4 (CI 21.9–35.0) |
Prevalence of diagnosed diabetes
- Remained stable
Prevalence of undiagnosed diabetes
- Remained stable
Proportion of diabetes that was undiagnosed
- Remained stable
Control among diagnosed DM: glycemic (HbA1c < 7.0 %), BP (< 130/80 mmHg), cholesterol (non-HDL < 130mg/dl), BP or lipid medication use
- Glycemia, BP, lipid control, and use of BP or lipid medication did not significantly change
Original publication
Diabetes prevalence, awareness, and control in the United States, 2017-2023. Diabetes Metab. Published 13 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →